{"nctId":"NCT01106690","briefTitle":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","startDateStruct":{"date":"2010-06"},"conditions":["Diabetes Mellitus, Type 2"],"count":344,"armGroups":[{"label":"Placebo/Sitagliptin","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Sitagliptin","Drug: Metformin","Drug: Pioglitazone"]},{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin","Drug: Metformin","Drug: Pioglitazone"]},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin","Drug: Metformin","Drug: Pioglitazone"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Canagliflozin","otherNames":[]},{"name":"Sitagliptin","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Pioglitazone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients must have a diagnosis of T2DM and be currently treated with PPAR gamma agent ((pioglitazone or rosiglitazone) and another anti-diabetes agent (metformin)\n* Patients in the study must have a HbA1c between \\>=7 and \\<=10.5% and a fasting plasma glucose (FPG) \\<270 mg/dL (15 mmol/L)\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* or a severe hypoglycemic episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.069"},{"groupId":"OG001","value":"-0.89","spread":"0.069"},{"groupId":"OG002","value":"-1.03","spread":"0.070"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7% at Week 26","description":"The table below shows the percentage of patients with HbA1c\\<7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":null},{"groupId":"OG001","value":"46.9","spread":null},{"groupId":"OG002","value":"64.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":"2.785"},{"groupId":"OG001","value":"-26.8","spread":"2.796"},{"groupId":"OG002","value":"-33.2","spread":"2.817"}]}]}]},{"type":"SECONDARY","title":"Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26","description":"HOMA2-%B is a measure of beta cell function (the cells in the pancreas that produce and store insulin). The table below shows the least-squares (LS) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"1.833"},{"groupId":"OG001","value":"15.19","spread":"1.809"},{"groupId":"OG002","value":"18.14","spread":"1.790"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.3"},{"groupId":"OG001","value":"-2.8","spread":"0.3"},{"groupId":"OG002","value":"-3.8","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"1.033"},{"groupId":"OG001","value":"-5.30","spread":"1.036"},{"groupId":"OG002","value":"-4.70","spread":"1.044"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Triglycerides From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"4.1"},{"groupId":"OG001","value":"3.2","spread":"4.1"},{"groupId":"OG002","value":"-1.7","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26","description":"The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.4"},{"groupId":"OG001","value":"7.2","spread":"1.3"},{"groupId":"OG002","value":"8.9","spread":"1.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":115},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Back pain","Diarrhoea"]}}}